Pregabalin Sandoz

Selected form

Pregabalin

Method of action: Analgesic, Anticonvulsant, Antiepileptic

Treatment option: Pain, Generalized Anxiety Disorder, Neuropathic Pain, Anxiety&Panic Attacks, Seizure, Fibromyalgia, Partial Seizures, Epilepsy

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pregabalin Sandoz

Quick Facts

Property	Description
Active ingredient	Pregabalin
Form	Hard capsule (primarily)
Pharmacological class	Anticonvulsant, Gabapentinoid
General purpose	Nerve modulator
Origin	Synthetic structural analogue of GABA

What Type of Medicine is Pregabalin Sandoz?

Pregabalin Sandoz is a prescription-only pharmaceutical preparation containing the active ingredient Pregabalin. It is classified as an anticonvulsant and belongs to the Gabapentinoid class of drugs. The drug is a generic medicine manufactured by Sandoz, providing a bioequivalent formulation of Pregabalin. It is clinically recognized for its utility in managing conditions characterized by chronic nerve hyper-excitability.

Composition, Origin, and Pharmaceutical Form

The foundation of the medication is Pregabalin, a synthetic chemical compound that is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). This differentiates it from drugs that directly act on GABA receptors. Pregabalin Sandoz is most commonly supplied in the form of hard capsules for oral administration, although the active substance is also available in oral solution and extended-release tablet forms under different trade names. The capsule contains Pregabalin as a single product combined with pharmaceutical excipients, such as a solid powder blend, to ensure formulation stability.

General Purpose: Why is Pregabalin Used?

The general therapeutic purpose of Pregabalin is to function as a nerve modulator that helps to stabilize nerve signaling within the central nervous system (CNS). The compound achieves this by reducing the excessive release of excitatory neurotransmitters involved in nerve hyper-excitability. This action establishes Pregabalin as an agent often utilized to address persistent, nerve-related discomfort that is unresponsive to traditional pain treatments. Its primary function is to calm overactive nerves and diminish the strength of abnormal electrical signals, positioning it as an effective tool for controlling neurological excitability.

Regulatory References

NIH DailyMed

What side effects are possible with Pregabalin Sandoz?

Possible side effects and safety information

Adverse effects documented in regulatory sources for Pregabalin are formally categorized by frequency and the body system affected, providing a structured profile of potential reactions.

Adverse Reaction Scope

Classification	Examples of Officially Documented Effects
Very Common	Dizziness, Somnolence (drowsiness).
Common	Headache, Weight increase, Blurred vision, Peripheral oedema, Constipation, Dry mouth, Ataxia, Confusion, Euphoric mood.
System-Organ Classes	Primarily Nervous System Disorders, Psychiatric Disorders, Gastrointestinal Disorders, and Eye Disorders.

Serious Adverse Reactions (Label-Documented): The regulatory label explicitly details risks of Severe Skin Reactions (including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis) and Angioedema (swelling of the face, mouth, or throat). As with other anticonvulsants, a documented, small increased risk of Suicidal Ideation and Behavior is noted. Furthermore, Respiratory Depression has been reported, particularly when used alongside other Central Nervous System (CNS) depressants.

Population-Specific Safety Considerations: Dose modification is formally required for patients with Renal Impairment, as the medicine is eliminated by the kidneys. Older Adults may also require dose adjustment due to a higher likelihood of reduced renal function. The label notes that certain reactions, such as weight increase, may be observed more frequently in pediatric patients.

Time- and Exposure-Related Patterns: Dizziness and somnolence are noted in regulatory documents as more common during the initial period of treatment and dose escalation. The potential for physical dependence is documented, and rapid discontinuation may result in withdrawal symptoms.

Connection to the Official Safety Profile

This structured safety information establishes a risk profile defined primarily by the high frequency of CNS-related effects and specific constraints related to renal function. By defining risks via frequency tiers and System-Organ Classes, regulatory authorities provide a non-advisory, factual framework of the medicine’s documented safety characteristics, emphasizing caution regarding use with other CNS depressants and the potential for dependence.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes the overdose profile of Pregabalin, emphasizing the difference between isolated overdose and co-ingestion with other substances.

Documented Overdose Presentations

Symptoms reported following overdosage, even up to 8,000 mg when taken alone, are typically not associated with significant life-threatening clinical consequences. The most commonly reported symptoms include:

Central Nervous System (CNS) Effects: Somnolence (sleepiness), confusional state, restlessness, agitation, and vertigo.
Other Symptoms: Vomiting and hypotension.

Serious and Life-Threatening Outcomes

Severe and life-threatening outcomes, including coma, seizures, heart block, and death, have been reported. These severe outcomes are overwhelmingly associated with the co-ingestion of Pregabalin with other CNS depressants, such as alcohol or opioids.

Emergency Action and Management

There is no specific antidote for Pregabalin overdose. Treatment is supportive and symptomatic, focused on maintaining vital functions and monitoring the patient's clinical status. For severe exposures, particularly in patients with impaired kidney function, the drug can be effectively removed from the body using haemodialysis.

Immediate medical attention is required for any suspected overdose or if severe symptoms—such as respiratory difficulty, unresponsiveness (coma), or seizures—are present, especially if other sedating medications or alcohol were involved.

Therapeutic Uses of Pregabalin Sandoz

What Pregabalin Sandoz Treats: Main Uses and Benefits

Pregabalin Sandoz is commonly used to help manage symptoms related to heightened physiological activity across several key domains in adult and certain pediatric patients. The core therapeutic domains include managing chronic neuropathic discomfort (such as Diabetic Peripheral Neuropathy and Postherpetic Neuralgia), is used for managing partial-onset seizure activity in epilepsy, and is relevant for easing symptoms of Generalized Anxiety Disorder (GAD). It is also considered relevant for easing symptomatic manifestations in conditions presenting with systemic discomfort, such as Fibromyalgia.

The medication provides supportive relief when symptoms interfere with daily comfort, assisting with maintaining functional stability when symptoms are more noticeable. This is particularly relevant in conditions characterized by periods of heightened symptoms.

“This medication is applied across domains where additional symptomatic support is needed, and is relevant for managing symptoms that create noticeable functional strain.”

Quick Fact: Focus on Neurological Symptom Management
Primary Focus	Managing symptoms related to heightened physiological activity.
Symptom Type	Symptoms that may become intense or disruptive (e.g., burning, shooting pain).
General Benefit	Contributes to easing the overall symptom load.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Pregabalin Sandoz is an oral medication approved for use in adults (18 years of age and older). Official regulatory information specifies several patient groups for whom the medicine is contraindicated, not recommended, or requires special caution.

Contraindications and Restrictions

Classification	Population Group	Regulatory Status
Contraindicated	Individuals with known hypersensitivity or allergic reaction to pregabalin or any of the inactive ingredients (excipients).	Prohibited
Not Recommended	Children and adolescents under 18 years of age, as safety and efficacy have not been established.	Restricted use
Not Recommended	Pregnant women and breastfeeding women; effective contraception is required for women of childbearing potential due to potential risk to the fetus.	Restricted use

Special Considerations

Use requires special caution in patients with the following conditions, often necessitating a lower dosage or close monitoring:

Kidney impairment: Dosage must be adjusted based on renal function, as the drug is cleared by the kidneys.
Elderly patients (over 65 years): Increased risk of side effects like dizziness and falls; dose adjustment may be necessary due to reduced kidney function.
History of substance abuse or dependence: These patients must be monitored for signs of misuse.
Compromised respiratory function or those taking certain CNS depressants (e.g., opioids), due to an increased risk of severe respiratory depression.
Patients with specific rare hereditary metabolic disorders (e.g., galactose intolerance, Lapp lactase deficiency) due to the presence of excipients in the formulation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pregabalin's official interaction profile is characterized primarily by pharmacodynamic potentiation and physiological clearance dependencies, with minimal risk for traditional pharmacokinetic drug-drug interactions.

Pharmacodynamic and Additive Risks

Co-administration with other Central Nervous System (CNS) depressants, including opioid analgesics, benzodiazepines, and ethanol (alcohol), is associated with a risk of additive CNS effects, such as increased somnolence and severe respiratory depression, as documented in regulatory information. This combination may also lead to reduced lower gastrointestinal tract function when taken with opioids.

Caution is advised when co-administered with thiazolidinedione antidiabetic agents (e.g., pioglitazone), due to an officially documented additive risk of peripheral edema and weight gain. Furthermore, co-administration with ACE-inhibitors requires monitoring due to the potential for an increased risk of angioedema.

Pharmacokinetic and Clearance Information

Pregabalin has a low potential for classic pharmacokinetic interactions because it is eliminated mainly by renal excretion and does not significantly inhibit or induce major CYP P450 liver enzymes. The drug's clearance is directly proportional to creatinine clearance; this physiological dependency requires dose adjustments in patients with renal impairment. Although the hard capsule form may be taken with or without food, food intake decreases the rate of absorption (Cmax) but does not affect the total extent of absorption (AUC).

Mechanism of Action

Molecular Target: Modulation of the Alpha-2-Delta Subunit

The foundational mechanism involves Pregabalin binding specifically to the alpha2-delta subunit of presynaptic Voltage-Gated Calcium Channels (VGCCs). This binding functionally modulates the channel, thereby reducing the calcium ion influx critical for neurotransmitter release.

Mechanistic Cascade: Functional Reduction of Excitatory Release

By impairing the flow of calcium ions, Pregabalin diminishes the presynaptic release of key excitatory neurotransmitters, notably Glutamate, Norepinephrine, and Substance P. The action regulates the amount of neurotransmitter released, differing from mechanisms that block postsynaptic receptor reception.

Systemic Effect: Dampening of Pathological Neural Circuits

The net physiological consequence of reducing excitatory neurotransmitter release is the functional dampening of activity within hyperexcitable neural networks, particularly within the Central Nervous System. This modulation reduces the signal transmission in overactive nerve signaling pathways, resulting in a change in physiological dynamics driven by excessive electrical activity.

Dosage and Administration Information

How to Use Pregabalin Sandoz

Pregabalin Sandoz (pregabalin immediate-release capsules) is an oral-only medication, and its usage is strictly guided by established dosing protocols.

Official Administration Guidelines

Instruction Element	Official Requirement (Label-Based)
Route of Administration	Oral use only. Capsules must be swallowed whole with water.
Timing in Relation to Meals	Can be taken with or without food.
Standard Dosing Schedule	The Total Daily Dose (TDD) typically ranges from 150 mg to 600 mg. Therapy is initiated at a low starting dose (e.g., 150 mg/day) and gradually increased (titrated).
Frequency	The TDD must be administered in two divided doses (BID) or three divided doses (TID) to ensure proper drug levels.

Procedural Protocols and Adjustments

Treatment follows a required gradual adjustment pattern (titration) when starting and a gradual tapering protocol when discontinuing. Dose increases are implemented incrementally over an interval of typically three to seven days or one week. Discontinuation must be managed slowly, with the dose reduced over a minimum of one week.

Dose Modification in Specific Populations

The dosage must be reduced and individualized for patients with renal impairment, as the drug's clearance is directly proportional to creatinine clearance. Patients on haemodialysis require a supplementary dose immediately following the procedure. No dose adjustment is required for patients with hepatic impairment. Older adults may require dose reduction due to age-related changes in kidney function.

Recent Clinical Evidence

Pregabalin Sandoz: Recent Clinical Evidence

Pregabalin is an antiepileptic drug that is used in adults for the management of various conditions, including neuropathic pain and as an add-on therapy for partial seizures. Clinical trials and systematic reviews provide evidence regarding its effects in these specific patient populations.

Evidence in Neuropathic Pain

Research has explored the use of pregabalin for pain associated with nerve damage due to conditions such as diabetic peripheral neuropathy and postherpetic neuralgia (pain following shingles). In randomized, placebo-controlled trials, a higher proportion of participants receiving pregabalin reported a significant reduction in pain intensity (e.g., a 50% reduction) compared to those receiving a placebo.

Evidence also suggests an effect in central neuropathic pain resulting from spinal cord injury. Furthermore, studies on neuropathic pain frequently report that pregabalin use is associated with a reduction in patient-reported sleep interference scores compared to placebo.

Evidence in Other Approved Indications

In addition to neuropathic pain, pregabalin is studied for its use in fibromyalgia and Generalized Anxiety Disorder (GAD). For GAD, meta-analyses suggest that pregabalin is associated with reductions in anxiety symptoms as measured by the Hamilton Anxiety Rating Scale (HAM-A).

Safety and Adverse Events

Across multiple clinical trials, the most commonly reported side effects associated with pregabalin were central nervous system effects such as dizziness and somnolence (drowsiness). Peripheral edema (swelling in the limbs) and weight gain were also reported with greater frequency in the pregabalin groups compared to placebo groups. Most common adverse events typically appeared within the first few weeks of treatment. Patients should be monitored for these effects.

Frequently Asked Questions (FAQ)

Common questions about Pregabalin Sandoz (FAQ)

Q: Does Pregabalin Sandoz help with anxiety that is not generalized anxiety disorder (GAD)?

A: Official regulatory information specifies that Pregabalin is approved for the treatment of Generalized Anxiety Disorder (GAD) in adults. While GAD is the only anxiety condition listed in the approved indications, consulting a healthcare professional is recommended for specific anxiety concerns.

Q: How quickly does Pregabalin Sandoz typically start to show a noticeable effect for nerve pain?

A: Individual response varies, but clinical study data indicates that some patients treating nerve pain may begin to notice a decrease in their symptoms as early as the first week of treatment. The full therapeutic effect may be observed after a period of dose adjustment.

Q: How long does the effect of a single dose of Pregabalin Sandoz last?

A: The duration of action for a single dose is generally considered to be 8 to 12 hours. This aligns with the typical recommended dosing schedule of two or three times daily.

Q: What happens if I miss a dose of Pregabalin Sandoz?

A: If a dose is missed, official patient information advises taking it as soon as you remember. However, if it is almost time for your next scheduled dose (often within 1–2 hours), you should skip the missed dose and continue with your regular schedule. It is important not to take two doses at the same time to compensate for a missed dose.

Q: What are the signs of a serious allergic reaction to Pregabalin Sandoz, like angioedema?

A: Serious allergic reactions, including a condition called angioedema, require immediate medical attention. Signs may include swelling of the face, lips, gums, tongue, throat, or neck, difficulty breathing, or the appearance of a severe rash, hives, or blisters. If these signs are observed, immediate medical help should be sought.

Q: How long does it take for Pregabalin Sandoz to be mostly removed from the system?

A: Pregabalin has an average elimination half-life of approximately 6.3 hours. The half-life refers to the time it takes for the concentration of the medicine in the blood to decrease by half. This measurement helps determine how quickly the drug is cleared from the body.

Q: Does taking Pregabalin Sandoz affect the results of standard drug tests?

A: Pregabalin is generally not included in common, standard drug screenings, such as a 5- or 10-panel test. However, it can be detected if a laboratory performs a specific, specialized test for pregabalin.

Q: Is Pregabalin Sandoz considered a controlled substance?

A: Yes, in the United States, pregabalin is classified as a Schedule V controlled substance by the Drug Enforcement Administration (DEA). This classification indicates that the medicine has a lower potential for abuse relative to Schedule IV substances.

Q: Are there different release forms of pregabalin (e.g., immediate-release vs. extended-release)?

A: Yes. Pregabalin Sandoz is formulated as an immediate-release (IR) capsule. The active ingredient, pregabalin, is also available in some markets in an extended-release (ER) tablet form, which is typically sold under different brand names.

Q: Can Pregabalin Sandoz be taken safely with common over-the-counter pain relievers like paracetamol or ibuprofen?

A: Regulatory sources focus on interactions with prescription CNS depressants. No clinically significant pharmacokinetic interactions are generally noted for common non-prescription pain relievers like paracetamol or ibuprofen. As with any medicine combination, consulting a healthcare professional about co-administration is recommended.

Q: Does Pregabalin Sandoz interact with hormonal birth control pills?

A: The official product information does not document a formal interaction between pregabalin and hormonal contraceptives. This is because the drug is primarily eliminated by the kidneys and does not significantly interfere with the liver enzymes (CYP P450) that process birth control pills.

Q: Why does Pregabalin Sandoz have warnings related to breathing difficulties (respiratory depression)?

A: Warnings about respiratory depression (severe breathing difficulties) are included because this serious event has been reported. The risk is increased when Pregabalin is used alongside other medicines that slow down the Central Nervous System (CNS), such as opioids, or in patients with pre-existing lung or breathing problems.

Q: Is Pregabalin Sandoz effective for sciatica or general back pain, or only neuropathic pain?

A: Pregabalin is officially approved to treat types of neuropathic pain, which is pain caused by damaged nerves, such as pain from diabetic neuropathy. The approved indications are specific to neuropathic pain and do not include general musculoskeletal back pain.

Q: Can Pregabalin Sandoz cause changes to my heart rhythm?

A: While uncommon, regulatory documents list cardiac disorders in the side effect profile. Specifically, changes to heart rate, such as tachycardia (fast heart rate) or sinus bradycardia (slow heart rate), have been reported as adverse reactions.

Q: Does Pregabalin Sandoz affect blood sugar levels, especially in patients with diabetes?

A: Studies and official information indicate that increased blood glucose has been reported as an uncommon side effect. Furthermore, because weight gain is a known side effect, diabetic patients who experience weight increase may need their diabetes medication adjusted.

Q: What percentage of people experience the major side effects of Pregabalin Sandoz?

A: Regulatory documents use categories like 'Very Common' (more than 10% of patients) and 'Common' (1% to 10% of patients). For example, clinical trial data shows that dizziness was reported by approximately 22% to 31% of patients, and somnolence (drowsiness) by approximately 13% to 18% of patients.

Q: Can Pregabalin Sandoz cause skin problems or rashes?

A: Yes, rashes and hives may occur as part of a general allergic reaction. Additionally, rare but very severe skin reactions, including conditions like Stevens-Johnson Syndrome (SJS), have been reported in official safety information.

Q: Does Pregabalin Sandoz interact with anti-depressant medications like SSRIs?

A: Official safety information cautions against use with Central Nervous System depressants, as this can increase risks like drowsiness. However, specific interactions with SSRI-type antidepressants are not formally documented.

How should Pregabalin Sandoz be stored and disposed of?

How to Store and Dispose of Pregabalin Sandoz?

Pregabalin Sandoz must be stored under specific conditions to maintain stability and safety. The medicine requires storage at a controlled room temperature, typically stipulated as below 30°C or in some regions, not above 25°C. To protect the capsules from environmental degradation, they must be kept in the original container in a cool, dry place.

Storage Requirements

The most critical requirement for households is ensuring the medication remains out of the reach and sight of children, often requiring that the product be stored locked up.

Disposal Instructions

Disposal must adhere to regulatory protocols. Unused or expired capsules must not be discarded in household garbage or flushed down the toilet (wastewater). Instead, the medicine should be returned to a pharmacist or an official collection point for proper pharmaceutical waste disposal, following all local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.